Mass spectrometry-based proteomics and disease

Over many years Thermo Scientific™ Gas Analysis Mass Spectrometers have proven effective in monitoring bacterial and microbial processes.

Lack of cellular differentiation is a hallmark of many human cancers, including acute myeloid leukemia (AML). Strategies to overcome such differentiation blockade, a notion known as “differentiation therapy,” represent an alternative approach for treating a subset of AML patients, a disease marked by a dismal prognosis and limited therapeutic options.

In healthy tissue, a reservoir of stem cells gives rise to non-stem cells while simultaneously maintaining their own population. This enables potentially endless growth and recovery from damage. Cancer stem cells (CSC) sustain cancer growth in the same way as normal stem cells do in healthy tissues. They give rise to both CSC and non-CSC tumour cells, the latter which lack stemness but make up the bulk of a tumour. DNA damaging agents (radiation and chemotherapy) can stop tumour growth by killing non-CSC tumour cells but CSC are resistant to these treatments. Surviving CSC could cause cancer relapse and progression, resulting in higher rates of patient mortality. There is growing interest in developing treatments which are specifically effective against CSC.

The voyage of a cell or gene therapy from initial hypothesis to commercial delivery is complex and challenging. It requires a broad spectrum of scientific expertise, innovative technologies, and optimized processes to ensure these advanced therapeutics make it to market. In this GEN webinar, our panelists—two industry leaders—will discuss what it takes to develop a cell or gene therapy from concept to commercialization, alongside a conversation about innovations that are likely to shape the future of advanced therapy discovery and biomanufacturing.